MSHLIsatuximab Concentrate For Solution For Infusion 100 mg/5 mL and 500 mg/25 mL
Isatuximab in combination with pomalidomide and dexamethasone for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy.